Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM

IntroductionGlioblastoma (GBM) remains a deadly cancer with non-curative upfront treatment of radiation, resection, and chemotherapy. Not only has the standard of care for GBM patients not improved significantly over the past decade, life expectancy is less than 18 months, with no standard second-li...

Descripción completa

Detalles Bibliográficos

Autores principales:	Danielle R. Cook, Alina C. Boesteanu, Yibo Yin, Reiss Reid, Laura Roccograndi, Nadia Dahmane, Maria Martinez-Lage, Donald M. O’Rourke, Carl H. June, Laura A. Johnson
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2025-07-01
Colección:	Frontiers in Immunology
Materias:	chimeric antigen receptor (CAR) tumor microenvironment (TME) glioblastoma (GBM) checkpoint inhibition (CPI) fourth generation CAR ARMed CAR
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579925/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!